HealthCare Global Enterprises (HCG) Q2 2026 earnings summary

Executive summary

• Reported strong revenue growth of 16.9% year-over-year for Q2FY26 and 16.8% for H1FY26, driven by both established and emerging centers.

• Adjusted EBITDA increased by 18.4% in Q2FY26 and 19.3% in H1FY26, with margin expansion.

• Profit after tax declined due to higher depreciation and interest expenses from recent growth investments and acquisitions.

• Board approved unaudited standalone and consolidated financial results for the quarter and six months ended 30 September 2025.

• 7,537 equity shares allotted upon exercise of employee stock options under ESOP 2021.

Financial highlights

• Q2FY26 consolidated revenue reached Rs 6,470 mn, up 16.9% year-over-year; H1FY26 revenue at Rs 12,601 mn, up 16.8%.

• Standalone revenue from operations for Q2 FY26: ₹34,441 lakhs, up from ₹32,845 lakhs in Q2 FY25 (restated).

• Consolidated net profit for Q2 FY26: ₹2,066 lakhs, compared to ₹2,068 lakhs in Q2 FY25.

• Adjusted EBITDA for Q2FY26 was Rs 1,233 mn (19.1% margin); H1FY26 at Rs 2,352 mn (18.7% margin).

• EPS for Q2FY26 was 1.2; for H1FY26, 1.5.

Outlook and guidance

• Continued focus on expanding capacity and improving operational metrics, with new centers and technology investments.

• Board approved investment of up to ₹700 lakhs in Cancer Care Kenya Limited, subject to regulatory approvals.

• Ongoing capex in North Bangalore and Whitefield expected to drive future growth.

• Management recognized deferred tax credit of ₹960 lakhs in a subsidiary due to improved performance and future profit certainty.